Company Overview
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of a comprehensive suite of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions specifically designed for the animal health industry across the United States and international markets. The company operates within the Healthcare sector, classified under the industry of Drug Manufacturers - Specialty & Generic, which positions it as a specialized provider of essential pharmaceuticals and biological agents rather than a mass-market consumer drug manufacturer. Zoetis demonstrates significant scale with a market capitalization of $50.21B, annual revenue reaching $9.47B over the trailing twelve months, and an employment base comprising 14,500 employees. These valuation and revenue figures indicate that Zoetis commands a substantial position in the market, reflecting high investor confidence in its recurring revenue model and its status as a dominant player in the veterinary pharmaceutical landscape where competitors are often smaller or more fragmented.
Financial Health
The company reported revenue of $9.47B, net income of $2.67B, and EBITDA of $4.07B for the trailing twelve months, revealing a substantial gap between total revenue and final net income that highlights the impact of operating expenses, taxes, and interest costs on the bottom line. Free cash flow stands at $1.79B, which signifies strong financial flexibility allowing the company to fund research and development initiatives, manage debt obligations, and return capital to shareholders without relying on external financing. Profitability is underscored by a gross margin of 71.9%, an operating margin of 34.7%, and a profit margin of 28.2%; these figures collectively indicate a highly efficient cost structure with significant pricing power in a specialized market where high R&D and regulatory compliance costs are managed effectively. The balance sheet shows total cash of $2.31B against total debt of $9.31B, resulting in a debt-to-equity ratio of 279.59, which suggests a leveraged balance sheet typical for capital-intensive pharmaceutical firms rather than a conservative cash-rich stance. Despite the leverage, the current ratio of 3.03 indicates robust short-term liquidity, meaning the company holds sufficient current assets to cover its current liabilities more than three times over. Return on Equity is reported at 66.0% while Return on Assets sits at 15.3%, metrics that reveal exceptional management effectiveness in generating profits from shareholders' capital and utilizing the asset base to drive earnings growth.
Valuation Assessment
The stock trades with a trailing P/E ratio of 18.93 and a forward P/E of 15.10, implying that the market expects earnings growth in the future that will bring the valuation multiple down from current levels. The price-to-book ratio is 14.53, indicating that the market values the company at a significant premium over its book value, reflecting the high intangible value of its intellectual property, brand equity, and patent portfolio. Alternative valuation metrics include a price-to-sales ratio of 5.30 and an EV/EBITDA of 13.49, which suggest the company is priced similarly to other high-quality specialty drug manufacturers where revenue and cash flow generation are primary drivers of value. The stock has a 52-week high of $172.23 and a 52-week low of $113.63, and while the exact current price is not explicitly stated in the provided facts, the range defines the historical volatility boundaries within which the asset has traded. The beta value is 0.95, which means the stock's price volatility is slightly lower than the broader market, suggesting it may be less sensitive to general market fluctuations than the average equity.
Growth & Income
Revenue growth is recorded at 3.0% year-over-year while earnings growth is 6.1% year-over-year, indicating that earnings are expanding at a faster rate than revenue, which typically implies successful cost management, operational leverage, or margin expansion driving profitability. Zoetis pays a dividend yield of 1.9% with a payout ratio of 33.2%, a structure that suggests the payout is highly sustainable given the company's strong earnings growth and substantial free cash flow generation. The low payout ratio leaves ample room for the company to reinvest earnings into growth projects or reduce debt while still maintaining a consistent dividend policy for income-focused investors. The overall profile combines moderate top-line growth with accelerating earnings and a stable, sustainable dividend, positioning the asset as a balanced option for portfolios seeking both capital appreciation and income.